MA35698B1 - Novel composition of 3,4-diaminopyridine for the treatment of muscular fatigability associated with neurovegetative disorders. - Google Patents

Novel composition of 3,4-diaminopyridine for the treatment of muscular fatigability associated with neurovegetative disorders.

Info

Publication number
MA35698B1
MA35698B1 MA35915A MA35915A MA35698B1 MA 35698 B1 MA35698 B1 MA 35698B1 MA 35915 A MA35915 A MA 35915A MA 35915 A MA35915 A MA 35915A MA 35698 B1 MA35698 B1 MA 35698B1
Authority
MA
Morocco
Prior art keywords
diaminopyridine
fatigability
disorders
muscular
treatment
Prior art date
Application number
MA35915A
Other languages
French (fr)
Inventor
Benziane Hamid
E Douard Bruno
Flocard Frederic
Original Assignee
Univ Mohammed V Souissi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mohammed V Souissi filed Critical Univ Mohammed V Souissi
Priority to MA35915A priority Critical patent/MA35698B1/en
Priority to PCT/MA2013/000041 priority patent/WO2014185761A1/en
Publication of MA35698B1 publication Critical patent/MA35698B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’objet de l’invention concerne une nouvelle composition du 3,4-diaminopyridine (3,4-dap) la rendant stable et homogène, préparée sous forme de gélule pour traiter et maîtriser l’évolution du syndrome paranéoplasique myasthénique de lambert-eaton, caractérisé par une fatigabilité musculaire associée à des troubles neurovégétatifs. Ce médicament est aussi utilisé dans la fatigabilité de la sclérose en plaques, dans le botulisme et les syndromes myasthéniques congénitaux et dans les troubles d’alzheimer. La nouveauté intéresse aussi le protocole de dosage du principe actif et des excipients. La nouvelle composition du 3,4-dap le mélange est délivré sous forme de gélule, comprimé ou suspension buvable, ou autres formes galéniques.The object of the invention relates to a new composition of 3,4-diaminopyridine (3,4-dap) making it stable and homogeneous, prepared in capsule form for treating and controlling the evolution of the paraneoplastic myasthenic lambert-eaton syndrome. , characterized by muscle fatigability associated with neurovegetative disorders. This drug is also used in the fatigues of multiple sclerosis, botulism and congenital myasthenic syndromes and in alzheimer's disorders. Novelty also concerns the dosing protocol of the active ingredient and excipients. The new composition of 3,4-dap the mixture is delivered in the form of capsule, tablet or oral suspension, or other galenic forms.

MA35915A 2013-05-16 2013-05-16 Novel composition of 3,4-diaminopyridine for the treatment of muscular fatigability associated with neurovegetative disorders. MA35698B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MA35915A MA35698B1 (en) 2013-05-16 2013-05-16 Novel composition of 3,4-diaminopyridine for the treatment of muscular fatigability associated with neurovegetative disorders.
PCT/MA2013/000041 WO2014185761A1 (en) 2013-05-16 2013-12-05 Novel 3,4-diaminopyridine composition for treating muscle fatigability associated with neurovegetative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA35915A MA35698B1 (en) 2013-05-16 2013-05-16 Novel composition of 3,4-diaminopyridine for the treatment of muscular fatigability associated with neurovegetative disorders.

Publications (1)

Publication Number Publication Date
MA35698B1 true MA35698B1 (en) 2014-12-01

Family

ID=49943449

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35915A MA35698B1 (en) 2013-05-16 2013-05-16 Novel composition of 3,4-diaminopyridine for the treatment of muscular fatigability associated with neurovegetative disorders.

Country Status (2)

Country Link
MA (1) MA35698B1 (en)
WO (1) WO2014185761A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110548023A (en) * 2019-09-19 2019-12-10 天津科技大学 Application of cochineal acid in preparation of medicines for inhibiting beta-amyloid protein aggregation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
US6503931B1 (en) * 1999-02-09 2003-01-07 The Uab Research Foundation Use of 4-amino pyridine for treatment of peripheral neuropathies

Also Published As

Publication number Publication date
WO2014185761A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
MX2021004431A (en) Novel processes.
JP2015517488A5 (en)
JP2013520405A5 (en)
EA202090573A1 (en) COMPOSITIONS OF NIRAPARIBA
EA202090276A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANEMIA
PH12021551541A1 (en) Compositions and methods for treating neurodegenerative disorders
RU2013153140A (en) A NEW ASSOCIATION BETWEEN 4- {3- [CIS-HEXAHYDROCYCLOPENT [C] PYRROL-2 (1H) - IL] PROPOXY} BENZAMIDE AND ACETYLCHOLINESTERESIS INHIBITOR AND PHARMACEZERETIC CEREIS
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
EA201991490A1 (en) AROMATIC AMIDES OF CARBOXYLIC ACIDS AS BRAKININ B1 RECEPTOR ANTAGONISTS
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
FI3493812T3 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
EA201792237A1 (en) PHARMACEUTICAL COMPOSITIONS
JP2019529569A5 (en)
MA35698B1 (en) Novel composition of 3,4-diaminopyridine for the treatment of muscular fatigability associated with neurovegetative disorders.
EA201591653A1 (en) COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS USING DIPYRIDAMOL
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
JP7062804B2 (en) Treatment and / or prophylaxis for Lewy body disease
EA201991817A1 (en) Intranasal Composition Including Betagistin
MX2018003890A (en) Pharmaceutical compositions containing a muscle relaxant and a non-steroidal anti-inflammatory drug (nsaid).
JP2017530142A5 (en)
FI3137094T3 (en) Treatment and prevention of alzheimer's disease (ad)
EA201791458A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT
EA201792170A1 (en) INDOLA DERIVATIVES